Comment by agsqwe

I think what's meant here it's that the manufacturer chose to target specific patient groups (T2D) and commercial insurances to get the highest profit per dose. About 40% of adults in the US are obese, they could have made the drug available at much lower cost and get their profits from economies of scale. Instead, the production is low and the focus is narrow.